Onconetix, Inc. (ONCO) · Oct 26, 2026 · Other events
1-for-10 reverse split — Aggregate reverse split reaches the authorized 1-for-100 maximum
Onconetix’s reverse split cuts shares 10-for-1 on November 6, using its full authorized capacity without changing the underlying business.
Onconetix is a cash-hungry commercial-stage biotech trying to move Proclarix toward broader U.S. commercialization through Labcorp, while its latest quarterly filing says it has not established sustained positive cash flow and still needs significant capital.
This is capital-market maintenance, not business progress. The Board approved another 1-for-10 reverse split, effective November 6, 2026, reducing shares from about 5.9 million to roughly 589,000. 〔0〕 〔1〕
The filing uses the company’s full approved reverse-split capacity. Combined with the 1-for-10 split completed in May, this reaches the stockholders’ authorized aggregate maximum of 1-for-100. 〔2〕 The direction was therefore partly known rather than a surprise. Onconetix previously said its May split was primarily intended to address Nasdaq’s minimum-bid requirement, so the new action appears to be another attempt to preserve listing flexibility, although this filing does not state that rationale explicitly.
It does not add funding, revenue, or a Proclarix milestone. Authorized shares remain at 250 million, so the split changes the share count and trading mechanics—not the company’s assets, ownership economics, commercialization progress, or financing position. 〔3〕
Bottom line: The action may help maintain market access, but it does not advance Proclarix or solve Onconetix’s funding challenge. The main message is continued capital-structure pressure, not an operating development.
Reverse split effective November 6, 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!